Holen Sie sich die Stockscreener-App
21.31
0.19%
0.04
Handel nachbörslich:
21.26
-0.05
-0.23%
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
DAWN stock jumps 66% on $2.5B buyout offer from Servier - MSN
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story - Sahm
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
Halper Sadeh LLC is Investigating Whether DAWN, SEM, EWCZ, FONR are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ - Carroll County Mirror-Democrat
Day One Biopharmaceuticals gains amid takeover speculation - MSN
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition - Investing.com Canada
Servier to acquire Day One Biopharmaceuticals for $2.5 billion - Investing.com Nigeria
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Day One Biopharmaceutical (DAWN) Downgraded to Neutral by HC Wai - GuruFocus
Day One (DAWN) soars 100% on $2.5-billion merger - MSN
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - Finviz
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now - TechStock²
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - TradingView
DAWN Stock Downgraded by Wedbush with Price Target Adjustment | - GuruFocus
Wedbush Reaffirms Neutral Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen - MarketBeat
Servier acquires International Biotech's Day One for USD2.5 billion - marketscreener.com
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
Day One Biopharma Earnings Call Highlights Ojemda Surge - TipRanks
Top Small Cap Stocks To Add to Your WatchlistMarch 7th - MarketBeat
Key deals this week: Diana Shipping, Day One Biopharmaceuticals, Hudbay Minerals and more - Seeking Alpha
Pharmaceutical Stocks To ResearchMarch 7th - MarketBeat
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - MSN
Knott David M Jr Grows Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to "Hold" at Wedbush - MarketBeat
Servier to acquire Day One Biopharmaceuticals for $2.5 billion By Investing.com - Investing.com Canada
Day One Biopharmaceuticals stock hits 52-week high at 21.12 USD - Investing.com Canada
Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger - Yahoo Finance
Day One Biopharmaceuticals (DAWN) Stock Surges 66% on Servier's $2.5 Billion Acquisition Deal - International Business Times Australia
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push - ET Pharma
Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion - Pulse 2.0
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc.DAWN - Business Wire
User - The Chronicle-Journal
Day One Biopharmaceuticals, Inc. (DAWN): A Hold Rating Amid Emerging Potential - 富途牛牛
DAWN: Cowen Downgrades Day One Biopharmaceuticals to Hold March 2026 - Meyka
Servier Adds To Rare Cancers Portfolio With Proposed Day One Buyout - Citeline News & Insights
Day One Biopharmaceuticals (DAWN) Stock Jumps 66% After Servier Acquisition Deal - MEXC
DAWN Stock Quote Price and Forecast - CNN
JonesTrading Reiterates Hold Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Why A 'White Knight' Could Still Fight For Day One Bio - Investor's Business Daily
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - marketscreener.com
Day One Biopharmaceuticals (DAWN) Stock Soars 66% on Servier Buyout Agreement - MEXC
Assessing Day One Biopharmaceuticals (DAWN) Valuation After OJEMDA’s Positive EMA Opinion And Licensing Progress - simplywall.st
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Is there any upside left in DAWN stock as it soars 65%? - Invezz
Pharmaceutical Stocks Worth WatchingMarch 6th - MarketBeat
Top Medical Stocks To Follow TodayMarch 6th - MarketBeat
How a Bay Area company won a drug approval and a $2.5 billion buyout in eight yearsSan Francisco Business Times - The Business Journals
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio - Yahoo Finance
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) - PR Newswire
Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio - Contract Pharma
TD Cowen downgrades Day One Biopharmaceuticals stock on Servier deal By Investing.com - Investing.com Canada
Traders Buy Large Volume of Call Options on Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Oppenheimer reiterates Day One Biopharmaceuticals stock rating on Servier deal - Investing.com Nigeria
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):